CompareMarketResearchRequest a sample
Home / Healthcare / Metered Dose Inhaler

Healthcare · Market report

Metered Dose Inhaler Market Size, Share and Forecast 2026-2036

The global metered dose inhaler market is worth USD 17.9 bn in 2026 and is forecast to reach USD 29.1 bn by 2036, growing at a 5.0% CAGR. United States is the largest country market and Combination inhalers is the largest by drug class segment.

USD 17.9 bnMarket size 2026
USD 29.1 bnForecast 2036
5.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global metered dose inhaler market is worth USD 17.9 bn in 2026 and is forecast to reach USD 29.1 bn by 2036, growing at a 5.0% CAGR. United States is the largest country market and Combination inhalers is the largest by drug class segment.

ScopePressurised metered dose inhalers delivering asthma and COPD drugs, including bronchodilators, corticosteroids and combination inhalers, branded and generic.
IndustryHealthcare
Value 2025USD 17.0 bn
Value 2026USD 17.9 bn
Value 2036USD 29.1 bn
CAGR 2026-20365.0%
Volume 2026679 million units
Volume 20361,052 million units
Average price 2026USD 26.3 per unit
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Metered Dose Inhaler market size and forecast, 2026-2036

Exhibit 1The global metered dose inhaler market is forecast to grow from USD 17.9 bn in 2026 to USD 29.1 bn by 2036, a rise of 63%Global market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 5.0%
Metered Dose Inhaler market value, 2025 to 2036Market value by year. 2025: USD 17.0 bn; 2026: USD 17.9 bn; 2027: USD 18.7 bn; 2028: USD 19.7 bn; 2029: USD 20.7 bn; 2030: USD 21.7 bn; 2031: USD 22.8 bn; 2032: USD 23.9 bn; 2033: USD 25.1 bn; 2034: USD 26.4 bn; 2035: USD 27.7 bn; 2036: USD 29.1 bn. Compound annual growth rate 2026 to 2036: 5.0%.202517.9 bn202622.8 bn203129.1 bn20365.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 17.9 bn
2027USD 18.7 bn
2028USD 19.7 bn
2029USD 20.7 bn
2030USD 21.7 bn
2031USD 22.8 bn
2032USD 23.9 bn
2033USD 25.1 bn
2034USD 26.4 bn
2035USD 27.7 bn
2036USD 29.1 bn

Metered Dose Inhaler market segmentation

By drug class

Exhibit 2Combination inhalers is the largest segment by drug class, with 38.0% of 2026 revenueEstimated share of 2026 global revenue, by drug class
Metered Dose Inhaler market share by drug class, 2026Share of 2026 revenue by drug class. Combination inhalers: 38.0%; Short-acting bronchodilators: 24.0%; Inhaled corticosteroids: 20.0%; Long-acting bronchodilators: 18.0%.Combination inhalers38.0%Short-acting bronchodilators24.0%Inhaled corticosteroids20.0%Long-acting bronchodilators18.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Short-acting bronchodilators24.0%18.4%USD 4.3 bn2.2%
Long-acting bronchodilators18.0%19.3%USD 3.2 bn5.7%
Inhaled corticosteroids20.0%17.7%USD 3.6 bn3.7%
Combination inhalers38.0%44.7%USD 6.8 bn6.7%

By access

Exhibit 3Generic adds the most revenue by access, growing from USD 5.7 bn in 2026 to USD 11.4 bn by 2036Estimated revenue in USD by access, 2026 and 2036 forecast
Metered Dose Inhaler market by access, 2026 and 2036Revenue by access in 2026 and 2036. Branded: USD 11.1 bn in 2026, USD 15.8 bn in 2036, change +43%; Generic: USD 5.7 bn in 2026, USD 11.4 bn in 2036, change +99%; Authorised generic: USD 1.1 bn in 2026, USD 1.9 bn in 2036, change +73%.20262036 forecastChangeBranded+43%11.1 bn15.8 bnGeneric+99%5.7 bn11.4 bnAuthorised generic+73%1.1 bn1.9 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Branded62.0%54.5%USD 11.1 bn3.6%
Generic32.0%39.1%USD 5.7 bn7.1%
Authorised generic6.0%6.4%USD 1.1 bn5.6%

By dose counter

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Without dose counter44.0%30.0%USD 7.9 bn1.1%
Integrated dose counter42.0%52.0%USD 7.5 bn7.3%
Add-on dose counter14.0%18.0%USD 2.5 bn7.7%

By therapy area

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Asthma48.0%46.0%USD 8.6 bn4.5%
COPD44.0%44.0%USD 7.9 bn5.0%
Other respiratory conditions8.0%10.0%USD 1.4 bn7.4%

By propellant

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Legacy HFA propellant72.0%30.0%USD 12.9 bn-3.8%
Low-warming HFA propellant20.0%40.0%USD 3.6 bn12.5%
Next-generation low-impact propellants8.0%30.0%USD 1.4 bn19.8%

Top 25 countries for metered dose inhaler by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 85.0% of 2026 revenue and the 25 countries below together hold 95.8%.

Exhibit 4United States is the largest country market at USD 7.5 bn in 2026, and the three largest countries hold 58.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Metered Dose Inhaler market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 7.5 bn, 42.0%; China: USD 1.8 bn, 10.0%; Japan: USD 1.1 bn, 6.0%; Germany: USD 892 mn, 5.0%; United Kingdom: USD 892 mn, 5.0%; France: USD 714 mn, 4.0%; India: USD 714 mn, 4.0%; Italy: USD 536 mn, 3.0%; Canada: USD 536 mn, 3.0%; Brazil: USD 536 mn, 3.0%.United States7.5 bn 42.0%China1.8 bn 10.0%Japan1.1 bn 6.0%Germany892 mn 5.0%United Kingdom892 mn 5.0%France714 mn 4.0%India714 mn 4.0%Italy536 mn 3.0%Canada536 mn 3.0%Brazil536 mn 3.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 7.5 bn42.0%USD 11.6 bn4.4%
2ChinaUSD 1.8 bn10.0%USD 3.7 bn7.5%
3JapanUSD 1.1 bn6.0%USD 1.5 bn3.5%
4GermanyUSD 892 mn5.0%USD 1.3 bn3.9%
5United KingdomUSD 892 mn5.0%USD 1.3 bn3.9%
6FranceUSD 714 mn4.0%USD 1.0 bn3.9%
7IndiaUSD 714 mn4.0%USD 1.8 bn9.5%
8ItalyUSD 536 mn3.0%USD 785 mn3.9%
9CanadaUSD 536 mn3.0%USD 814 mn4.3%
10BrazilUSD 536 mn3.0%USD 960 mn6.0%
11SpainUSD 302 mn1.7%USD 488 mn4.9%
12AustraliaUSD 270 mn1.5%USD 436 mn4.9%
13South KoreaUSD 232 mn1.3%USD 375 mn4.9%
14NetherlandsUSD 186 mn1.0%USD 299 mn4.9%
15MexicoUSD 154 mn0.9%USD 247 mn4.9%
16TurkeyUSD 143 mn0.8%USD 230 mn4.9%
17RussiaUSD 118 mn0.7%USD 192 mn5.0%
18PolandUSD 105 mn0.6%USD 172 mn5.0%
19Saudi ArabiaUSD 87 mn0.5%USD 140 mn4.8%
20SwedenUSD 79 mn0.4%USD 125 mn4.8%
21ArgentinaUSD 70 mn0.4%USD 113 mn5.0%
22BelgiumUSD 55 mn0.3%USD 90 mn5.0%
23SwitzerlandUSD 50 mn0.3%USD 81 mn5.0%
24IndonesiaUSD 45 mn0.2%USD 73 mn5.0%
25South AfricaUSD 37 mn0.2%USD 61 mn5.0%
Rest of worldUSD 746 mn4.2%USD 1.2 bn5.0%
Exhibit 5United States and China account for 53% of the USD 11.2 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Metered Dose Inhaler market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 17.9 bn. United States: +USD 4.1 bn; China: +USD 1.9 bn; India: +USD 1.1 bn; Japan: +USD 441 mn; Brazil: +USD 424 mn; 20 other countries: +USD 2.9 bn; Rest of world: +USD 463 mn. Market value 2036: USD 29.1 bn.Market value 202617.9 bnUnited States+4.1 bnChina+1.9 bnIndia+1.1 bnJapan+441 mnBrazil+424 mn20 other countries+2.9 bnRest of world+463 mnMarket value 203629.1 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • GSK
  • AstraZeneca
  • Chiesi
  • Teva Pharmaceutical
  • Cipla
  • Viatris
  • Boehringer Ingelheim

Group 2: Regional and specialist players

  • Lupin
  • Glenmark
  • Orion
  • Zydus Lifesciences
  • Hikma
  • Amneal
  • Sun Pharmaceutical
  • Aptar Pharma

Group 3: Emerging and niche players

  • Kindeva
  • Presspart
  • Koura
  • Recipharm

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the metered dose inhaler market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.0% is calculated from the resulting values.

The market is divided by drug class, by access, by dose counter, by therapy area, by propellant. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the metered dose inhaler market?

The global metered dose inhaler market is estimated at USD 17.0 bn in 2025 and USD 17.9 bn in 2026.

How fast will the metered dose inhaler market grow?

It is forecast to reach USD 29.1 bn by 2036, a compound annual growth rate of 5.0% from 2026, an increase of USD 11.2 bn.

Which country is the largest market for metered dose inhaler?

United States is the largest market by revenue at USD 7.5 bn in 2026, 42.0% of the global total. The three largest countries together hold 58.0%.

Which country is growing fastest?

Among the ten largest markets, India is growing fastest at 9.5% a year from 2026 to 2036.

Which metered dose inhaler segment is largest?

In the by drug class split, Combination inhalers is the largest segment with 38.0% of 2026 revenue.

Who are the leading metered dose inhaler companies?

Global leaders include GSK, AstraZeneca, Chiesi, Teva Pharmaceutical.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Mental Health Services Micro Balloon Catheter →

All Healthcare markets →

Request a sample